71 – 80 of 2271
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc for the treatment of hemophilia B
- Contribution to journal › Scientific review
-
Mark
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
- Contribution to journal › Debate/Note/Editorial
-
Mark
Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis
- Contribution to journal › Letter
-
Mark
Evidence that CD36 is expressed on red blood cells and constitutes a novel blood group system of clinical importance
- Contribution to journal › Article
-
Mark
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression
- Contribution to journal › Letter
-
Mark
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
- Contribution to journal › Article
-
Mark
Historical perspective on von Willebrand disease
(2024) p.1-6
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Textbook of von Willebrand Disease : Basic and Clinical Aspects
- Book/Report › Anthology (editor)
-
Mark
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
- Contribution to journal › Article
